US FDA to head off cell/gene therapy manufacturing issues with pre-IND meetings; Republic of Ireland will “chase any opportunities” for business partners stemming from Brexit, even while hoping UK reconsiders EU departure; AMAG won’t follow the flibanserin PR approach with newly submitted female sexual dysfunction drug bremelanotide; United Neuroscience CMO Ajay Verma says Alzheimer’s trial setbacks are “learnings,” with progress toward novel therapies moving faster than it has for cancer and HIV.
The US FDA is rolling out a new program aimed at proactively heading off manufacturing hurdles that could slow the development of cell and gene therapies.
The initiative within the Center for Biologics Evaluation and Research (CBER) will encourage early meetings between sponsors and the agency to discuss chemistry, manufacturing and controls issues, as well...